cd4bs
mAbexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 7, 2024 (NCT06267872)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Envelope glycoprotein gp160ANTAGONIST
Q993A8 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06267872 | Phase 1 | Oct 7, 2024 | Access to Advanced Health Institute (AAHI), Department of Health and Human Services, Duke University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Access to Advanced Health Institute (AAHI) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2024 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2024 |
5 organizations
Page 1 / 1